TFRC and pancreatic neoplasm: Systemic delivery of the TfR-targeting nanoparticles resulted in more siRNA being delivered to pancreatic tumors in a murine xenograft model compared to nanoparticles without the TfR antibody (Pirollo et al., 2007).